National guidelines recommend adjuvant intravesical Bacillus Calmette-Guérin (BCG) therapy for higher-risk non–muscle-invasive bladder cancer (NMIBC). Although a survival benefit has not been ...
Non-muscle-invasive bladder cancer (NMIBC) has a high risk of recurrence and progression among patients without adequate Bacillus Calmette-Guérin.
In this phase IIb parallel cohort study, patients with BCG-unresponsive carcinoma in situ (CIS) with/without papillary disease received TAR-200 monotherapy (Cohort 2 [C2]), TAR-200 plus cetrelimab (C1 ...
TAR-200 is a first-in-class intravesical drug-releasing system designed to provide sustained delivery of gemcitabine in the bladder. TAR-200 alone or in combination with cetrelimab (PD-1 inhibitor) ...
Human bladder. Design element for medical concept, bladder cancer, cystitis, human excretory system. Wireframe low poly style. Abstract vector illustration on dark blue background. Investigators ...
Aidixi combined with BCG showed 100% clinical complete response rates at three and six months in high-risk NMIBC patients with HER2 expression. Event-free survival at six months was 100% for patients ...
ANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer -- Commercial availability achieved within two months of announcing MENA ...
Immunotherapy uses the power of your immune system to fight your cancer. One type of immunotherapy is called an immune checkpoint inhibitor. Your immune system has built-in checkpoints that help it ...
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. ImmunityBio, Inc. is one of the best ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results